Abstract: The present invention relates to inhibitors of the interaction between H. pylori HopQ and a member of the carcinoembryonic antigen-related cell adhesion molecule (CEACAM) family as well as to immunogenic compositions based on H. pylori HopQ. The present invention further relates to the use of the inhibitors and immunogenic compositions for preventing or treating a disease or disorder caused by or associated with H. pylori.

Abstract: The present invention discloses a method for assessing the capacity of a substance to treat or prevent hepadnavirus infection. A reporter virus carrying genetic information for a first fragment of a recombinase and a reporter cell expressing a second fragment of the recombinase are used. When the reporter virus infects the reporter cell, the two fragments of the recombinase associate and excise a stop cassette that is flanked by two recombination sites and blocks the expression of a reporter gene. Accordingly, the present invention relates to a method of assessing the capacity of a substance to treat or prevent hepadnavirus infection, a hepadnavirus comprising a nucleic acid encoding a first fragment of a recombinase and a mammalian hepatocyte or hepatoma cell comprising a nucleic acid encoding a second fragment of a recombinase and a nucleic acid comprising a stop cassette flanked by two recombination sites fused to a reporter gene.

Abstract: The present invention relates to a method for preparation of a functionalized surface comprising the steps: a) coating of a carrier with a least one polymer selected from a polyanionic or polycationic polymer, b) addition of at least one compound to the coated carrier of step a), c) exposing the at least one polyanionic or polycationic polymer on the coated carrier of step b) to an organic solvent, resulting in compaction of the at least one polyanionic or polycationic polymer and thereby encapsulating the at least one compound, d) reversible cross-linking of the at least one polyanionic or polycationic polymer of step c) with at least one cross-linker; e) removal of the organic solvent. Furthermore, the invention relates to a functionalized surface, a functionalized surface for use in medicine and a method for releasing a compound ex vivo.

Abstract: The present invention relates to specific complexes comprising heavy metal ions having an atomic number of 23 or higher and 83 or lower (in particular Ag1+, Ba2+, Pb2+, Gd3+ and Bi3+) and one or more hematein ligand(s). In particular, the invention relates to the use of the complexes as ex vivo contrast agents for a computed tomography scanning of a biological sample. Moreover, the invention relates to specific ex vivo methods for investigating a biological sample by means of computed tomography scanning methods, wherein the method comprises staining the biological sample with a solution comprising one or more of the complex(es); or wherein the method comprises staining the biological sample with a staining solution comprising hematein, and separately contacting the biological sample with one or more staining solution(s) comprising one or more heavy metal ions having an atomic number of 23 or higher and 83 or lower (in particular Ag1+, Ba2+, Pb2+, Gd3+ and Bi3+).

Abstract: The invention relates to a method for operating a memory assembly. A physical address is received. The physical address is associated with a first memory segment of a memory assembly. The physical address is modified to a modified physical address. The modified physical address is associated with a second memory segment of the memory assembly.

Abstract: A sensor (10) comprises a waveguide (20) having a longitudinal axis and an end face (21), the waveguide (20) comprising a Bragg grating (23). The sensor comprises at least one reflector (24) on the end face (21) of the waveguide (20). An optical resonator (25) is formed by the Bragg grating (23), the at least one reflector (24), and an inner portion of the optical resonator (25) between the Bragg grating (23) and the at least one reflector (24). The inner portion of the optical resonator (25) extends within a portion of the waveguide (20). The sensor (10) comprises a detector (32) configured to detect at least one spectral characteristic of the optical resonator (25) or a change of at least one spectral characteristic of the optical resonator (25).

Abstract: The present invention relates to compounds which bind and/or inhibit prostate-specific membrane antigen (PSMA) comprising at least one group electron dense substituent (EDS), and at least one moiety which is amenable to radiolabeling; and therapeutic and diagnostic uses thereof.

Abstract: The present invention relates to peptides, in particular amyloid inhibitory peptides, and to pharmaceutical compositions comprising such peptides. Furthermore, the present invention relates to such peptides, in particular such amyloid inhibitory peptides, for use in methods of treating or diagnosing neurodegenerative diseases such as Alzheimer's disease, or for use in a method of treating or diagnosing type 2 diabetes. Furthermore, the present invention also relates to a kit for the in-vitro or in-vivo detection and, optionally, quantification of amyloidogenic polypeptides, amyloid fibrils or amyloid aggregates, and/or for the diagnosis of Alzheimer's disease or type 2 diabetes in a patient.

Abstract: The present invention relates to inhibitors of the interaction between H. pylori IIopQ and a member of the carcinoembryonic antigen-related cell adhesion molecule (CEACAM) family as well as to immunogenic compositions based on H. pylori HopQ. The present invention further relates to the use of the inhibitors and immunogenic compositions for preventing or treating a disease or disorder caused by or associated with H. pylori.

Abstract: A process for polymerizing ?-butyrolactone that includes contacting racemic ?-butyrolactone or an enantiomer thereof with a catalyst/initiator system which includes a rare earth metal, a chiral ligand, at least one nucleophilic ligand, optionally at least one solvent ligand, and optionally an alkali based co-catalyst. The chiral ligand is an enantiomer of a unit of formula I Each Rz independently is substituted or unsubstituted linear C1-C20 alkyl, or substituted or unsubstituted branched, or cyclic C3-C20 alkyl, substituted or unsubstituted C6-C20 aryl, substituted or unsubstituted C5-C20 heteroaryl, or halogen. Each Ra independently is H, Me+, (MeZ)+, wherein Z is a charge equalizing anion, or wherein two Ra together are alkaline earth metal, wherein Me+ is alkali metal or alkaline earth metal.

Abstract: The present invention relates to an enzymatic process for the modification of free fatty acids (FFAs) derived from renewable feedstocks of bio-based oils. Specifically, the invention describes the hydrolysis of any bio-based oil, such as high oleic sunflower oil (HOSO), to FFAs, containing high amounts of oleic acid (OA), which is further hydrated to 10-hydroxystearic acid (10-HSA).

Abstract: An antenna comprises a ground plane, a first antenna element and a second antenna element, wherein the first antenna element and the second antenna element are arranged for emitting and/or receiving electromagnetic radiation at a design wavelength with a first polarization direction and a second polarization direction, respectively, the second polarization direction being different from the first polarization direction, wherein the first and second antenna elements each comprise pairs of resonator elements having sidewalls facing a corresponding probe arranged in each pair of resonator elements, wherein one resonator element of each pair of resonator elements is shared between the first and second antenna elements and the respective probes of the first and second antenna elements are arranged on different sides of the shared resonator element.

Abstract: Disclosed herein is a device (100) for multicolor optical imaging of a sample (102) with wavelength-dependent optical path length enhancement, the device (100) comprising an optical resonator (106) for enhancing an optical path length, wherein the optical resonator (106) has a first finesse at a first wavelength and a second finesse at a second wavelength; a sample holder (104) for mounting the sample (102) in the optical resonator (106), wherein the sample holder (104) is configured to hold the sample (102) such that an optical axis (112) of the optical resonator (106) intersects with the sample (102);a first imaging system (114) for imaging the sample (102) at the first wavelength with a first imaging technique, and a second imaging system (126) for imaging the sample (102) at the second wavelength with a second imaging technique, wherein the second wavelength is different from the first wavelength; wherein the first finesse and the second finesse are chosen such that the optical resonator (106) enhances a

Abstract: According to the present invention there is provided a method for enantiomeric enrichment of a mixture of two enantiomers of a chiral compound, the method comprises the application of the mixture of two enantiomers of a chiral compound onto a surface of a support material for producing a coated support, the determination a first value of an optical activity (OA0) of the coated support, the irradiation of the coated support with a light beam having an intensity at least higher than a desorption threshold of one of the enantiomers from the coated support, wherein, if the support material is achiral, the light beam is circularly polarized and, if the support material is chiral, the light beam is unpolarized, linearly polarized or circularly polarized, and the determination of a second value of the optical activity (OAe) of the coated support after said irradiation, wherein the second value of the optical activity (OAe) differs from the first value of the optical activity (OA0).

Abstract: The present invention relates to a ligand-SIFA-chelator conjugate, comprising, within in a single molecule three separate moieties: (a) one or more ligands which are capable of binding to a disease-relevant target molecule, (b) a silicon-fluoride acceptor (SIFA) moiety which comprises a covalent bond between a silicon atom and a fluorine atom, and (c) one or more chelating groups, optionally containing a chelated nonradioactive or radioactive cation.

Abstract: The present invention relates to a nucleic acid molecule comprising a low repetitive nucleotide sequence encoding a proline/alanine-rich amino acid repeat sequence. The encoded polypeptide comprises a repetitive amino acid sequence that forms a random coil. The nucleic acid molecule comprising said low repetitive nucleotide sequences can further comprise a nucleotide sequence encoding a biologically or pharmacologically active protein. Further, the present invention provides for selection means and methods to identify said nucleic acid molecule comprising said low repetitive nucleotide sequence. The present invention also relates to a method for preparing said nucleic acid molecules. Also provided herein are methods for preparing the encoded polypeptide or drug conjugates with the encoded polypeptide using the herein provided nucleic acid molecules. The drug conjugate may comprise a biologically or pharmacologically active protein or a small molecule drug.

Abstract: A method for identifying the switch topology of multiple energy storage module connected in parallel and/or in series, which respectively have at least one energy storage element, each module has a switch element for selectively activating and deactivating the module and a unique identifier, wherein each module is assigned to a module string in that a total current flowing across the switch topology is checked, and individual modules are activated successively via the switch element until the total current is detectable.

Abstract: The invention relates to a method of determining the dissociation rate constant (koff) of a receptor molecule R on a target cell using a combination of reversible and irreversible cell labeling. The invention further relates to a cell comprising such a receptor molecule R, wherein the cell has bound to it such a combination of cell labeling. The invention further relates to a kit and an apparatus useful in performing the methods of the invention. The invention further relates to a method of isolation a high-avidity T cell.

Abstract: The present invention refers to a secretion-competent mutein of the ?-subunit of human Interleukin 27 and to a human heterodimeric Interleukin 27. The present invention further refers to a nucleic acid molecule comprising a nucleotide sequence encoding a secretion-competent mutein of the ?-subunit of human Interleukin 27 or the human heterodimeric Interleukin 27, to a host cell containing a nucleic acid molecule comprising a nucleotide sequence encoding a secretion-competent mutein of the ?-subunit of human Interleukin 27 or of the human heterodimeric Interleukin 27. The invention also refers to an immune modulator comprising a secretion-competent mutein of the ?-subunit of human Interleukin 27 or of the human heterodimeric Interleukin 27, to the respective use thereof as well as to a method of producing said secretion-competent muteins and to a secretion-incompetent mutein of the ?-subunit of mouse Interleukin 27 and a secretion-competent mutein of the ?-subunit of mouse Interleukin 27.

Abstract: A molecular machine comprising a movement part (2) including a first molecular element (4), a second molecular element (5), and a linking element (6) for constraining a relative movement of the first molecular element (4) and the second molecular element (5), and a control part configured to generate an electrical field around the movement part (2), wherein the first molecular element (4) is fixed relative to the control part, wherein the second molecular element (5) is movable relative to the first molecular element (4) in at least one degree of freedom, and wherein the second molecular element (5) is electrically charged such that the second molecular element (5) aligns to said electrical field.